With Merck & Co. largely propping up supplies of the bladder cancer-fighting bacteria Bacillus Calmette-Guérin (BCG) in the U.S., ImmunityBio has received the FDA all-clear to help pick up the ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Gene's lead asset shows high complete response rates in BCG-unresponsive NMIBC patients. Click here to read why ENGN stock is ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its ...

Arne Dedert / Picture Alliance / Getty Images Merck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of estimates. Revenue and adjusted earnings ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Merck’s 2025 guidance fell short of Wall Street expectations. - Spencer Platt/Getty Images Investors have taken to punishing pharma companies that appear unable to gauge demand for their top ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per ...

The company's key drug, Gardasil, is facing slowing sales in China. Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly beat ...

BCG chief executive Christoph Schweizer told the Financial Times there had been a rise in M&A deals on the firm’s “radar” and that it expected an increase in due diligence and preparatory ...